Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure

A pharmaceutical composition comprising as active ingredients:

• at least one ingredient selected from the group consisting of a prostaglandin analog, a β-blocker, an adrenergic agent, an α2-adrenergic receptor agonist, a miotic agent, a carbonic anhydrase inhibitor and a cholinergic agonist;
• and
• a compound represented by Formula III:
• including any pharmaceutically acceptable salt, hydrate, solvate, enantiomer and diastereomer thereof, and any mixtures thereof, and a pharmaceutically acceptable carrier, wherein:
• X is H or OH;
• R′ is selected from the group consisting of OH, C1-C6 alkyl, C1-C6 haloalkyl (C1-C6 alkyl substituted with at least one halo), —(CRbRc)nSi(Ra)3, —(CRbRc)n-C(═Y)—NR1R2, —(CRbRc)n-C(═Y)—NHOH, —(CRdRe)n-C(═Y)—COOR3, —NHC(═Y)NR1R2 and —(CRbRc)n-NH2;
• Y is O or S;
• R1, R2 and R3 are each independently H or a C1-C4 alkyl;
• Ra is a C1-C4 alkyl;
• Rb, Rc and Rd are each independently selected from H, a C1-C4 alkyl and a C1-C4 hydroxyalkyl;
• Re is selected from a C1-C4 alkyl and a C1-C4 hydroxyalkyl;
• and
• n is 0, 1 or 2.